Skip to main content
Dr. Parag H. Mehta
Search
Board Review · Medicine Simplified

Pulmonary

11 high-yield topics. Open a topic to review its pearls.

Pulmonary Function Tests

Obstructive vs restrictive

PFT Patterns

  • Obstructive (COPD): low FEV1/FVC, high TLC, high RV
  • COPD: low DLCO; Asthma: normal DLCO
  • Restrictive (ILD): FEV1/FVC normal, low TLC, low DLCO
  • FEV1/FVC under 70 percent = obstructive

DLCO

  • Increased: alveolar hemorrhage, polycythemia, CHF
  • Decreased: COPD, ILD, PE, pulmonary HTN
  • Normal: asthma, extrathoracic restriction

Flow Volume Loops

  • Fixed obstruction: both loops flattened (tracheal stenosis)
  • Extrathoracic: inspiratory flattening (vocal cord dysfunction)
  • Intrathoracic: expiratory flattening (tracheomalacia)

Arterial Blood Gases

Acid-base interpretation

Acidosis/Alkalosis

  • Check pH: acidosis under 7.4, alkalosis over 7.4
  • Anion gap = Na - (Cl + HCO3), normal 12
  • Winters formula: expected pCO2 = 1.5(HCO3) + 8 plus or minus 2

Anion Gap Causes (MUDPILES)

  • Methanol, Uremia, DKA, Paraldehyde, INH/Iron, Lactic acidosis, Ethylene glycol, Salicylates

Respiratory Compensation

  • Acute respiratory acidosis: pCO2 up 10, pH down 0.08, HCO3 up 1
  • Chronic: pCO2 up 10, pH down 0.03, HCO3 up 3
  • Metabolic alkalosis: check urine chloride

Asthma

Classification and treatment

Classification

  • Mild intermittent: 2 or fewer per week, albuterol PRN
  • Mild persistent: over 2 per week, add low-dose inhaled steroids
  • Moderate: daily, medium ICS + LABA
  • Severe: continual, high ICS + LABA + oral steroids

Special Presentations

  • Exercise-induced: inhaled B2-agonist before exercise
  • Aspirin-induced: asthma + polyps + ASA sensitivity, leukotriene inhibitors
  • ABPA: eosinophilia, IgE to Aspergillus, central bronchiectasis, steroids
  • Occupational: peak flow at work vs home

Severe Exacerbation

  • Pulsus paradoxus over 15, PCO2 over 40 (ominous), O2 sat under 90
  • Hospitalize, IV steroids, nebulized B2-agonists
  • Intubate if rising PCO2

COPD

GOLD staging and treatment

GOLD Classification

  • FEV1/FVC under 70 percent required
  • GOLD I: FEV1 80 or more; short-acting bronchodilator PRN
  • GOLD II: 50-80; add tiotropium + rehab
  • GOLD III: 30-50; add inhaled corticosteroid
  • GOLD IV: under 30; add long-term oxygen

Treatment Points

  • Smoking cessation: only measure that changes natural history
  • Oxygen: only therapy that improves survival (PaO2 under 55 or sat under 88)
  • Tiotropium superior; inhaled steroids decrease exacerbations
  • Pulmonary rehab improves tolerance (not survival)

Exacerbations

  • Increased dyspnea, sputum volume/purulence
  • H. influenzae, Moraxella, S. pneumoniae
  • Macrolides or fluoroquinolones (not erythromycin)
  • BiPAP before intubation

Interstitial Lung Disease

IPF, sarcoidosis, occupational

Upper vs Lower Zone

  • Upper: sarcoidosis, silicosis, berylliosis, ankylosing spondylitis
  • Lower: asbestosis, IPF, collagen vascular disease

IPF

  • Dry cough, dyspnea, clubbing, honeycombing
  • Restrictive PFTs, reduced DLCO, UIP pattern
  • No effective treatment; oxygen and transplant

Sarcoidosis

  • Non-caseating granulomas, hilar adenopathy
  • Increased CD4/CD8 on BAL, elevated ACE
  • Stage I: hilar adenopathy (60 percent remit)
  • Steroids if symptomatic/worsening PFTs
  • Diagnosis: transbronchial biopsy

Occupational Lung Disease

Asbestos, silica, beryllium

Asbestos

  • Shipyards, brakes; lower lobe, velcro crackles
  • Mesothelioma (no cigarette role); lung cancer (cigarettes multiply)
  • Pleural plaques = marker of exposure only

Others

  • Silicosis: sandblasting, upper lobe, eggshell calcifications, increased TB
  • Berylliosis: aerospace, sarcoid-like, lymphocyte transformation test
  • Coal workers: black lung

DVT and Pulmonary Embolism

Diagnosis and treatment

Risk Factors

  • Previous DVT = biggest risk
  • Virchow triad: stasis, endothelial injury, hypercoagulability
  • Factor V Leiden: most common inherited disorder
  • Knee replacement 70 percent, hip replacement 50 percent

Diagnosis

  • ABG: acute respiratory alkalosis, A-a gradient over 20
  • CXR: usually normal; Westermark sign, Hampton hump
  • EKG: sinus tachycardia (S1Q3T3 rare)
  • Spiral CT chest; gold standard pulmonary angiography

Treatment

  • Treat empirically if suspicion high
  • Heparin/LMWH bridge to warfarin 3-6 months
  • Thrombolytics if hypotension from massive PE
  • IVC filter: contraindication to anticoagulation or failure
  • Fat embolism (hip fracture) and amniotic fluid embolism: do NOT anticoagulate

Pulmonary Hypertension

Classification and treatment

Definition and Groups

  • Mean PA pressure over 25 mmHg at rest
  • Group I: PAH (idiopathic, drugs, connective tissue, HIV, portal HTN)
  • Group II: left heart disease
  • Group III: hypoxic (COPD, ILD, sleep apnea)
  • Group IV: chronic thromboembolic

Diagnosis and Treatment

  • Echo best screen; right heart cath definitive
  • Vasoreactivity testing
  • CCB only if proven responders
  • Bosentan (endothelin antagonist), sildenafil, epoprostenol
  • Anticoagulation if Group 1

Pneumonia

CAP, HAP, VAP

Community-Acquired

  • S. pneumoniae most common (rusty sputum)
  • Staph aureus: post-influenza, salmon-pink sputum
  • Klebsiella: currant jelly sputum, bulging fissure
  • Legionella: water sources, diarrhea, hyponatremia, urine antigen
  • Mycoplasma: young, bullous myringitis, cold agglutinins

CURB-65

  • Confusion, Urea over 19.6, RR over 30, BP low, age over 65
  • 0-1 outpatient, 2-3 inpatient, 4-5 ICU

HAP/VAP

  • HAP: over 48h after admission
  • VAP: over 48h after intubation
  • MDR organisms: MRSA, Pseudomonas, Acinetobacter
  • Prevention: elevate head of bed 45 degrees

Tuberculosis

Diagnosis, PPD, treatment

Clinical Forms

  • Primary: Gohn focus, usually asymptomatic
  • Latent: positive PPD, no symptoms, 10 percent lifetime reactivation
  • Reactivation: upper lobe/apical, cavitation
  • Progressive primary (HIV): lower lobe
  • Miliary: hematogenous, reticulonodular

PPD Interpretation

  • 5mm or more: HIV, close contacts, transplant, immunosuppressed
  • 10mm or more: IV drug users, immigrants, healthcare workers, DM
  • 15mm or more: no risk factors

Treatment

  • Latent: INH 9 months or rifampin 4 months
  • Active: RIPE x2 months, then INH + rifampin x4 months
  • Directly observed therapy improves adherence
  • HIV: use rifabutin instead of rifampin, DOT mandatory

Cystic Fibrosis and Bronchiectasis

Genetic lung diseases

Cystic Fibrosis

  • Autosomal recessive, CFTR gene (deltaF508)
  • Recurrent pneumonias (Staph, Pseudomonas)
  • Upper zone bronchiectasis, pancreatic insufficiency
  • Diagnosis: elevated sweat chloride over 60 x2
  • Burkholderia cepacia: contraindication to transplant

Alpha-1 Antitrypsin

  • Young non-smoker with COPD, lower zone bullae
  • Family history, ZZ homozygous
  • IV augmentation therapy
  • Kartagener: bronchiectasis + sinusitis + infertility + situs inversus